• EN
  • DA

Danish NationalResearch Database

  • Publications
  • Researchers
Example Finds records
water{} containing the word "water".
water supplies"{}" containing the phrase "water supplies".
author:"Doe, John"author:"{}" containing the phrase "Doe, John" in the author field.
title:IEEEtitle:{} containing the word "IEEE" in the title field.
bech{} containing the word "bech".
marie bech"{}" containing the phrase "marie bech".
orcid:0000-0002-5429-5292orcid:{} Having a particular ORCID
Need more help? Advanced search tutorial
  • Selected (0)
  • History

Evaluation of serum osteopontin level and gene polymorphism as biomarkers

    • Save to Mendeley
    • Export to BibTeX
    • Export to RIS
    • Email citation
Authors:
  • Prasmickaite, Lina ;
    Close
    unknown
  • Berge, Gisle ;
    Close
    unknown
  • Bettum, Ingrid J ;
    Close
    unknown
  • Aamdal, Steinar ;
    Close
    unknown
  • Hansson, Johan ;
    Close
    unknown
  • Bastholt, Lars ;
    Close
    Orcid logo0000-0001-5478-9826
    Oncology, Department of Clinical Research, Faculty of Health Sciences, SDU
  • Øijordsbakken, Miriam ;
    Close
    unknown
  • Boye, Kjetil ;
    Close
    unknown
  • Mælandsmo, Gunhild M
    Close
    unknown
Subtitle:
analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
DOI:
10.1007/s00262-015-1686-4
Abstract:
Malignant melanoma is highly aggressive cancer with poor prognosis and few therapeutic options. Interferon alpha (IFN-α) has been tested as adjuvant immunotherapy in high-risk melanoma patients in a number of studies, but its beneficial role is controversial. Although IFN-α treatment can prolong relapse-free survival, the effect on overall survival is not significant. However, a small subset of patients benefits from the treatment, signifying the need for biomarkers able to identify a responding subgroup. Here we evaluated whether serum osteopontin (OPN) could function as a biomarker identifying patients with poor prognosis that might benefit from IFN-α. The choice of osteopontin was based on the knowledge about the dual role of this protein in cancer and immune response, an apparent association between OPN and IFN signaling and a prognostic value of OPN in multiple other tumor types. Serum samples from 275 high-risk melanoma patients enrolled in the Nordic Adjuvant IFN Melanoma trial were analyzed for circulating OPN concentrations and OPN promoter polymorphisms in position -443. The potential relation between serum OPN levels, the genotypes and survival in non-treated patients and patients receiving adjuvant IFN-α was investigated. Although slightly better survival was observed in the treated patients that had high levels of OPN, the difference was not statistically significant. In conclusion, serum OPN (its level or the genotype) cannot distinguish melanoma patients with poor prognosis, or patients that might benefit from adjuvant treatment with IFN-α.
Type:
Journal article
Language:
English
Published in:
Cancer Immunology, Immunotherapy, 2015, Vol 64, Issue 6, p. 769-776
Keywords:
Female; Humans; Interferon-alpha; Male; Melanoma; Osteopontin; Polymorphism, Single Nucleotide; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Tumor Markers, Biological
Main Research Area:
Medical science
Publication Status:
Published
Review type:
Peer Review
Submission year:
2015
Scientific Level:
Scientific
ID:
2264549709

Full text access

  • Doi Get publisher edition via DOI resolver
Checking for on-site access...

On-site access

At institution

  • University southern denmark

Metrics

Feedback

Sitemap

  • Search
    • Statistics
    • Tutorial
    • Data
    • FAQ
    • Contact
  • About
    • Institutions
    • Release History
    • Cookies and Personal Data
  • Open Access
    • The Danish Open Access Indicator

Copyright © 1998–2018.

Fivu en